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Abstract
Highly-lethal outbreaks of multi drug-resistant (MDR) and extensively drug-resistant (XDR)
tuberculosis are increasing. Whole-genome sequencing of KwaZulu-Natal MDR and XDR outbreak
strains prevalent in HIV patients by the Broad Institute identified 22 novel mutations which were
unique to the XDR genome or shared only by the MDR and XDR genomes and not already known
to be associated with drug-resistance. We studied the 12 novel mutations which were not located in
highly-repetitive genes to identify mutations that were truly associated with drug-resistance or likely
to confer a specific fitness advantage. None of these mutations could be found in a phylogenetically
and geographically diverse set of drug–resistant and susceptible M. tuberculosis isolates, suggesting
that these mutations are unique to the KZN clone. Examination of the 600 bp region flanking each
mutation revealed 26 new mutations. We searched for a convergent evolutionary signal in the new
mutations for evidence that they emerged under selective pressure, consistent with increased fitness.
However, all but one rare mutation were monophyletic, indicating that the mutations were markers
of strain-phylogeny rather than fitness or drug-resistance. Our results suggest that virulent XDR
tuberculosis in immunocompromised HIV patients can evolve without generalizable fitness changes
or other XDR-specific mutations.
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Introduction
Multi drug-resistant (MDR) and extensively drug resistant (XDR) Mycobacterium
tuberculosis is an expanding problem in many countries [1]. The high mortality rates associated
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with some drug-resistant strains are particularly worrisome. The recently described XDR
tuberculosis outbreak in Tugela Ferry KwaZulu-Natal, South Africa, had a mortality rate of
98% among patients infected with the human immunodeficiency virus (HIV) [2]. It is not
known whether epidemic drug-resistant strains have evolved special mechanisms that facilitate
drug-resistance acquisition, maintain fitness or promote person-to-person transmission.
Conventional wisdom has held that M. tuberculosis acquires MDR and XDR through a stepwise
accumulation of chromosomal mutations that each confers resistance to individual drugs [3].
Single-step MDR mutations have not been conclusively identified. Resistance mutations have
been shown to be associated with a fitness “cost” in many bacteria including M. tuberculosis,
where the cost appears to be dependent on specific mutation and strain type [4]. Several in
vitro studies have suggested that clinical M. tuberculosis has found ways to compensate for
the fitness cost of antibiotic resistance [5]. However, except for the relatively rare occurrence
of ahpC promoter up mutations, no molecular mechanisms that maintain fitness in drug-
resistant clinical M. tuberculosis have been identified.
Comparative whole genome sequencing studies have the potential to identify biologically
significant mutations in drug-resistant M. tuberculosis strains by providing an unbiased scan
of the total genomic changes that accompany resistance acquisition. The Broad Institute has
recently released the complete genomic sequences of a Tugela Ferry XDR outbreak isolate and
two related MDR and drug susceptible (DS) isolates [6,7]. Comparing the three Tugela Ferry
genomes to a representative DS isolate (strain F11) from the same geographic region revealed
15 mutations that were unique to the Tugela Ferry XDR isolate (XDR-specific mutations), and
18 mutations that were shared by both the Tugela Ferry XDR and MDR isolates but were not
present in the DS isolate (XDR/MDR-specific mutations). As expected, many of these
mutations mapped to known drug-resistance targets and/or had previously known associations
with drug resistance. However, 22 mutations were completely novel and did not occur in genes
that had been described previously in association with drug resistance. It is tempting to assume
that these novel mutations represent unidentified drug resistance mutations, new mutations
relevant to XDR evolution or fitness adaptations.
Mutations that are highly selected during MDR and XDR evolution should not be restricted to
the Tugela Ferry XDR strain or its related MDR isolate. Rather, these biologically important
mutations should occur with detectible frequencies in unrelated MDR and XDR M.
tuberculosis strains from around the world. This hypothesis is supported by the observation
that the common mutations that are known to cause resistance to the first line anti-tuberculosis
drugs isoniazid, ethambutol [8], and rifampin (data not shown) can be found in different and
unrelated populations, reflecting convergent evolution.
Methods
Identification of mutations specific to the extensively drug resistant (XDR) or both the XDR
and multi drug resistant (MDR) isolates sequenced from Tugela Ferry KwaZulu-Natal, South
Africa
Polymorphisms unique to the XDR strain or shared by the XDR and MDR strains were obtained
from the publicly available comparative analysis of the XDR (KZN 605), MDR (KZN 1435),
and drug-sensitive (DS) (KZN 4207) strains published by the Microbial Sequencing Center at
the Broad Institute [7].
Selection of clinical M. tuberculosis isolates for the study
A total of 35 drug-resistant and 34 pan-susceptible isolates were selected from a collection of
clinical M. tuberculosis isolates obtained from reference laboratories or major medical centers
in Afghanistan (n=1), Australia (n=1), China (n=1), Colombia (n=14), India (n=6), Korea
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(n=1), Mexico (n=10), New York City (n=6), Philippines (n=1), Somalia (n=1), Spain (n=3),
Sudan (n=1), Texas (n=22), and Vietnam (n=1) [9,10]. Effort was made to include multi-drug
resistant isolates where possible. Each of the isolates was assigned to one of 10 SNP cluster
group/sub-group using nine SNP markers developed for this purpose [11] and then mapped
onto the previously described phylogenetic tree [12] (Fig. 2). Additional six extensively drug-
resistant isolates were obtained Mulago Hospital, Uganda (n=1), and National Masan
Tuberculosis Hospital, Korea (n=5). All isolates were subjected to susceptibility testing as
described previously [10].
Detection of mutations in M. tuberculosis study isolates
Primers were designed to amplify an approximately 600bp region flanking the mutations of
interest per the Mycobacterium tuberculosis H37Rv genome sequence (GenBank Accession
NC_000962). Additionally, the 1357bp Rv3616c-Rv3617 intergenic region was sequenced in
all isolates. The entire length of each gene identified by the Tugela Ferry MDR-XDR mutations
was sequenced in the six XDR isolates. PCR amplification was performed using Hotstar Taq
polymerase (Qiagen Inc.). The PCR products were sequenced using standard dye terminator
chemistry and analyzed on an automated DNA sequencer (3700 DNA Analyzer, Applied
Biosystems). All mutations were confirmed by sequencing the reverse strand, except when
they were abundant, in which case a subset of isolates were retested for each mutation.
Results
We tested for mutations that were shared by the Tugela Ferry strain and unrelated M.
tuberculosis strains by looking for the Tugela Ferry XDR-specific and XDR/MDR-specific
mutations in a diverse set of M. tuberculosis MDR and XDR isolates as well as DS controls.
Tugela Ferry mutations that were found to be present in other sequenced DS M. tuberculosis
genomes and mutations that were already known to confer resistance to individual antibiotics
were excluded, as our interest was to discover new resistance-associated mutations. We also
excluded six mutations in the PPE/PE-PGRS gene family and the other repetitive genes,
because these genes are known to be hyper-variable even in DS M. tuberculosis and they would
be unlikely to have a relationship to drug resistance [13]. Thus, our final study focused on five
synonymous, five non-synonymous and two non-coding mutations in seven genes/regions with
known functions and five hypothetical genes/regions (Fig. 1).
To ensure that mutations were studied in a highly diverse set of M. tuberculosis strains, we
selected five or six drug-resistant and five DS M. tuberculosis isolates from each of the four
major M. tuberculosis phylogenetic groups, and two or three drug-resistant and two or three
DS isolates from each of the five phylogenetic sub-groups as described previously [12] (Fig.
2). Thirty-one of the 35 drug-resistant isolates were MDR, three were resistant to at least two
drugs and one was mono-resistant (Table S1). Six XDR isolates from phylogenetic SNP cluster
group (SCG) 2 and SCG 3a isolated from two different geographic locations (Korea and
Uganda) were also analyzed giving a total of 41 drug-resistant and 34 drug susceptible strains.
We did not find any of the 12 Tugela Ferry XDR-specific or XDR/MDR-specific mutations in
any of the 41 drug-resistant isolates in our study (Table 1). The complete absence of any of
these mutations in our widely representative sample of drug-resistant isolates strongly suggests
that these mutations do not have broad biological relevance in the evolution of XDR
tuberculosis. We also considered the possibility that the mutations observed in the Tugela Ferry
XDR strain might identify new gene regions rather than specific new mutations that play
important roles in drug-resistance. To this end, we sequenced approximately 600 bp of DNA
flanking each of the 12 mutations in the 41 drug-resistant isolates. We also sequenced the entire
1357bp Rv3616c-Rv3617 intergenic region. The DNA sequencing revealed 26 new mutations
in five genes or intergenic regions (Rv0103c, Rv2000, intergenic-Rv3616c-Rv3617, Rv3806c
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and Rv3921c) (Table 2). Nine of these mutations were present in more than one drug-resistant
isolate, while 13 mutations were identified in only one drug-resistant isolate. The same regions
were then sequenced in the 34 phylogenetically-matched drug-susceptible M. tuberculosis
isolates (Table 2). We found that eight of the nine mutations previously identified in more than
one drug-resistant isolate were also present in at least one drug-susceptible isolate, strongly
suggesting that these mutations were not associated with drug resistance. Thus, only the −992
G to T mutation in the Rv3616c-Rv3617 intergenic region was present in more than one drug-
resistant isolate but not present in any drug-susceptible isolate; however this mutation was
present at a 2/40 (5%) frequency and occurred in isolates from the same SCG as described
below. Three new mutations which were only present in the drug susceptible isolates were also
identified. Of these, one occurred in more than one drug-susceptible isolate.
Commonly occurring drug-resistance associated mutations have a distinct phylogenetic
distribution, suggestive of convergent evolution, compared to neutral mutations in M.
tuberculosis. Common resistance-associated mutations can be shown to arise independently
multiple times in broadly representative tuberculosis populations and cannot be traced back to
a single common ancestor in a phylogenetic analysis. Mutations that are not strongly selected
will be monophyletic and appear to have arisen only once in this population [8]. We performed
a phylogenetic analysis of each of the 11 mutations which were found in more than one M.
tuberculosis isolate, examining their distribution within the context of the entire 75 isolate
study set (Fig. 3a to 3d). Each mutation either mapped to a single phylogenetic branch or
mapped to adjoining branches. This included the −992 G to T mutation in the Rv3616c-Rv3617
intergenic region which was confined to SCG 1 (Fig. 3b). With one exception, when a mutation
was present on adjoining branches, at least one of the branches was 100% mutant suggesting
a single mutational event in a common ancestor. These results provide strong evidence that the
new mutations discovered in the drug resistant isolates are associated with strain phylogeny
rather than drug resistance. The lone exception occurred with the −706 T to C mutation in the
Rv3616c - Rv3617 intergenic region. This mutation, which was present in both MDR and DS
isolates was found in 50% of SCG 1 isolates as well as one isolate on the contiguous SCG 3a
branch. The absence of a complete monophyletic distribution leaves open the possibility that
this mutation has multiple ancestries and developed under selective pressure. However, the
lack of any association to drug resistance, its relative paucity in the study set and its complete
absence on most of the phylogeny suggest that this is not an important fitness mutation.
Eleven of the 33 Tugela Ferry MDR-XDR and XDR mutations had been previously associated
with drug resistance. Two of these mutations at katG315 and inhA −15 which are known to
cause resistance to the antituberculosis drug isoniazid were examined in our 75 drug-resistant
and DS strain set. These known resistance-associated mutations were well represented among
the drug-resistant isolates, but were not present in any of the DS isolates. The phylogenetic
distribution of the katG315 and inhA −15 mutations also contrasted markedly with the
distribution of the mutations that were newly identified in this study (Fig. 3e and 3f). Both the
katG and the inhA mutations were distributed on multiple phylogenetic branches, consistent
with previous studies [8]. The marked contrast in the distribution of established drug resistance
mutations compared to the mutations newly discovered here provides further evidence that the
new mutations are not associated with drug resistance or a significant fitness advantage.
We also sequenced the entire length of each gene identified by the Tugela Ferry MDR-XDR
mutations in our six XDR isolates. Five additional mutations in Rv0020c, Rv0663, Rv1145
and Rv2000 were identified. Four mutations were present in multiple isolates and one mutation
was only found in a single isolate. We examined our DS isolates matched by phylogenetic
group for each of these mutations. All four of the mutations present in more than one XDR
isolate were also found in one or more DS isolates belonging to the same SCGs as the XDR
isolates (Table 3).
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One of the mutations which we observed most frequently was located at position −41 (G to T)
of the Rv3616c - Rv3617 intergenic region. This mutation was of interest even though it was
present in both susceptible and resistant isolates because the Rv3612c-Rv3616c operon appears
to be required for the secretion of ESAT-6 and CFP-10 which are vital to M. tuberculosis
virulence [14], because the mutation was present in all of the highly virulent SCG2-Beijing
clade isolates, and because the −41 mutation was in close proximity to the −55 mutation
described in the Tulega Ferrry XDR isolate. These observations prompted us to investigate if
this mutation had any effect on ESAT-6 secretion. However, we did not find any difference in
the transcription of Rv3616c or the extra-cellular secretion of ESAT-6 using RT-PCR and
western blot analysis, respectively in either −41 G to T mutant or wild type isolates (data not
shown).
Discussion
This study represents the first comprehensive analysis, to our knowledge, of XDR and MDR-
XDR mutations discovered by the Broad Institute KZN XDR sequencing project. It suggests
that XDR tuberculosis can evolve in a virulent form without generalizable fitness changes or
other XDR-specific mutations. The Broad Institute sequencing effort provided a unique
opportunity to determine whether secondary mutations that predispose to MDR and/or
compensate for the fitness costs of resistance-conferring mutations develop in tandem with
XDR evolution. We were unable to identify any mutations that the Tugela Ferry XDR strain
shared with unrelated drug-resistant M. tuberculosis isolates other than loci already known to
be associated with drug-resistance. Thus, the Tugela Ferry genome sequence does not appear
to provide new generalizable insights into the evolution of XDR tuberculosis. Furthermore,
our examination of the gene and gene region surrounding the MDR-XDR and XDR mutations
did not reveal any additional candidates for secondary resistance or fitness mutations. However,
it was not possible to completely rule out either of these functions for mutations which were
only detected one time in the study set.
It remains possible that the Tugela Ferry strain developed an unusual set of adaptations to XDR
that were not present in any of the other drug-resistant strains tested. However, both heightened
transmission and high mortality have been repeatedly described when immunocompromised
patients are exposed to drug-resistant M. tuberculosis. Therefore, it is more likely that the
Tugela Ferry strain does not contain unique genetic adaptations to XDR. Rather, the widespread
distribution and high mortality of this strain can probably be attributed to the health status of
the host and possibly, the quality and availability of medical treatment. Our results do not
completely rule out the possibility that drug-resistant M. tuberculosis develops mutations that
support MDR/XDR acquisition and maintain fitness. Selection for mutations of this type may
be dictated by treatment and/or host factors that were not widespread in the Tugela Ferry XDR
outbreak. For example, fitness mutations may not be required to maintain full virulence in
immunocompromised hosts. Furthermore, it is possible that certain mutations in known
resistance-associated genes can provide drug-resistance without attenuation (such as katG315
mutations [15]) or can predispose to resistance developing across drug classes (such as
mutations in embB306 [9,16]). Both of these mutations were found in the Tugela Ferry genome,
and these already established mutations rather than the new mutations of unknown function
may fully explain the ability of this strain to be transmitted and cause disease. It will require
further genome comparisons of additional XDR isolates, particularly from HIV negative
patients to resolve these questions.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Flow chart for selection of genes included in the study
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Figure 2. Phylogenetic locations of the study isolates
Each branch shows the location of SNP cluster groups (SCGs), including subgroups as defined
by an analysis of 212 SNP markers on 324 M. tuberculosis isolates [12]. Study isolates were
placed on the phylogenetic tree using 9 SNP markers identified for this purpose [11]. The
positions of the M. tuberculosis reference strains 210, CDC1551, and H37Rv and of M.
bovis strain AF2122/97 are indicated. Positions of the drug-susceptible (DS), multi-drug
resistant (MDR) and extensively-drug resistant (XDR) are also indicated. The number of drug-
resistant including MDR (R), pan-susceptible (S) and extensively drug-resistant (X) isolates
from each SCG are indicated.
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Figure 3.
Panels A–D Phylogenetic distribution of the new mutations identified in the drug-
resistant and susceptible isolates. The number of isolates located on each branch of the
phylogenetic tree shown in Fig. 2 (and the % of isolates on that branch which contain that
mutation) is shown according to the indicated color code. Relevant linked SNP cluster groups
are highlighted in dark color. Nucleotide positions indicated are relative to the start site of
respective genes. Panels E and F: Phylogenetic distribution of the inhA promoter and
katG315 mutations. The locations of each of the 75 study isolates on the phylogenetic tree
shown in Fig. 2 that contained either the katG315 or the inhA promoter region SNPs are shown
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according to the indicated color code. Nucleotide positions indicated are relative to the start
site of respective genes.
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Table 1
Frequency of the Tugela Ferry-strain XDR and XDR-MDR specific mutations in a diverse sample of 41 drug-
resistant M. tuberculosis isolates.
H37Rv gene H37Rv location Mutation # Mutation type
Rv0020c 24125 C/T 0 S (L440L)
Rv0103c 122107 G/A 0 NS (G23S)
Rv0663 756757 C/T 0 S (Y207Y)
Rv1145 1272321 C/A 0 NS (L25I)
Rv2000 2246032 T/C 0 NS (L275P)
Rv2141c 2401402 C/A 0 S (G109G)
Rv3459c 3879441 C/G 0 S (A84A)
Rv3471c 3889150 C/A 0 NS (D64E)
Rv3806c 4269271 T/C 0 NS (V188A)
Rv3921c 4409995 C/T 0 S (Y25Y)
Rv0571c and Rv0572cInt 664929 C/A 0 Intergenic
Rv3616c and Rv3617Int 4056430 T/C 0 Intergenic
#: Number of mutants
Int: Intergenic
NS: Non-synonymous
S: Synonymous
J Infect Dis. Author manuscript; available in PMC 2011 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Motiwala et al. Page 12
Ta
bl
e 
2
M
ut
at
io
ns
 id
en
tif
ie
d 
in
 st
ud
y 
is
ol
at
es
 b
y 
se
qu
en
ci
ng
 a
pp
ro
xi
m
at
el
y 
60
0 
bp
 fl
an
ki
ng
 th
e 
Tu
ge
la
 F
er
ry
-s
tra
in
 X
D
R
 a
nd
 X
D
R
-M
D
R
 m
ut
at
io
n 
lo
ci
.
H
37
R
v 
ge
ne
a
M
ut
at
io
n
R
es
is
ta
nt
*
Su
sc
ep
tib
le
M
ut
at
io
n 
ty
pe
n
#
%
n
#
%
−4
, G
 to
 T
41
1
2
33
0
-
In
te
rg
en
ic
R
v0
10
3c
−4
2,
 T
 to
 C
41
1
2
33
0
-
In
te
rg
en
ic
−1
19
, G
 to
 A
41
1
2
33
0
-
In
te
rg
en
ic
R
v2
00
0
65
6,
 C
 to
 A
41
10
24
34
6
18
N
S 
(P
21
9Q
)
70
8,
 T
 to
 G
41
2
5
34
1
3
S 
(A
23
6A
)
−4
1,
 G
 to
 T
b
40
18
45
33
10
30
In
te
rg
en
ic
−1
06
, d
el
 A
b
40
1
3
33
0
-
In
te
rg
en
ic
−2
60
, A
 to
 G
b
40
1
3
33
0
-
In
te
rg
en
ic
−3
18
, C
 to
 A
b
40
10
25
33
5
15
In
te
rg
en
ic
R
v3
61
6c
-R
v3
61
7I
nt
−6
61
, T
 to
 C
b
41
2
5
32
2
6
In
te
rg
en
ic
−7
06
, T
 to
 C
b
41
4
10
32
2
6
In
te
rg
en
ic
−8
36
, G
 to
 A
b
41
1
2
32
0
-
In
te
rg
en
ic
−8
47
, C
 to
 T
b
41
0
0
32
1
3
In
te
rg
en
ic
−9
92
, G
 to
 T
b
40
2
5
30
0
-
In
te
rg
en
ic
22
8,
 T
 to
 C
41
7
17
32
3
9
S 
(R
76
R
)
R
v3
80
6c
44
7,
 A
 to
 C
41
7
17
34
5
15
N
S 
(E
14
9D
)
51
7,
 T
 to
 G
41
1
2
34
0
-
N
S 
(S
17
3P
)
52
1,
 A
 to
 C
41
1
2
34
0
-
N
S 
(K
17
4T
)
53
6,
 T
 to
 G
41
1
2
34
0
-
N
S 
(I
17
9S
)
71
3,
 T
 to
 C
41
1
2
34
0
-
N
S 
(F
23
8S
)
86
4,
 G
 to
 A
41
1
2
34
0
-
S 
(A
28
8A
)
J Infect Dis. Author manuscript; available in PMC 2011 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Motiwala et al. Page 13
H
37
R
v 
ge
ne
a
M
ut
at
io
n
R
es
is
ta
nt
*
Su
sc
ep
tib
le
M
ut
at
io
n 
ty
pe
n
#
%
n
#
%
11
6,
 C
 to
 G
41
0
0
33
2
6
N
S 
(A
39
G
)
28
9,
 C
 to
 T
41
1
2
33
0
-
S 
(L
97
L)
R
v3
92
1c
33
6,
 G
 to
 C
41
1
2
33
0
-
N
S 
(M
11
2I
)
41
0,
 G
 to
 T
41
1
2
33
1
3
N
S 
(G
13
7V
)
46
8,
 G
 to
 A
41
0
0
33
1
3
S 
(P
15
6P
)
T
ot
al
 n
o.
 o
f i
so
la
te
s
41
34
* I
nc
lu
de
s 6
 X
D
R
 is
ol
at
es
n:
 N
um
be
r o
f i
so
la
te
s s
eq
ue
nc
ed
#:
 N
um
be
r o
f m
ut
an
ts
In
t: 
In
te
rg
en
ic
 re
gi
on
N
S:
 N
on
−s
yn
on
ym
ou
s
S:
 S
yn
on
ym
ou
s
a N
o 
m
ut
at
io
ns
 fo
un
d 
in
 th
e 
60
0b
p 
fla
nk
in
g 
re
gi
on
 o
f R
v0
02
0c
, R
v0
57
1c
–R
v0
57
2c
In
t , 
R
v0
66
3,
 R
v1
14
5,
 R
v2
14
1c
, R
v3
45
9c
, R
v3
47
1c
b P
os
iti
on
 is
 g
iv
en
 in
 re
fe
re
nc
e 
to
 th
e 
tra
ns
la
tio
na
l s
ta
rt 
si
te
 o
f R
v3
61
6c
J Infect Dis. Author manuscript; available in PMC 2011 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Motiwala et al. Page 14
Ta
bl
e 
3
A
dd
iti
on
al
 m
ut
at
io
ns
 id
en
tif
ie
d 
in
 X
D
R
 st
ud
y 
is
ol
at
es
 a
nd
 th
ei
r p
re
se
nc
e 
in
 m
at
ch
ed
 D
S 
co
nt
ro
ls
.
H
37
R
v 
ge
ne
M
ut
at
io
n
X
D
R
Su
sc
ep
tib
le
M
ut
at
io
n 
ty
pe
n
#
%
n
#
%
R
v0
02
0c
70
7-
24
, 1
8b
p 
de
l
6
6
10
0
6
6
10
0
6 
am
in
o 
ac
id
 d
el
et
io
n
R
v0
66
3
10
03
, C
 to
 A
6
5
83
6
3
50
N
S 
(R
33
5S
)
10
46
, A
 to
 G
6
6
10
0
6
5
83
N
S 
(D
34
9G
)
R
v1
14
5
71
1,
 G
 to
 A
6
1
17
7
0
-
S 
(L
23
7L
)
82
9,
 In
s A
6
6
10
0
7
6
86
Fr
am
e 
sh
ift
T
ot
al
 n
o.
 o
f i
so
la
te
s
6
8
X
D
R
: E
xt
en
si
ve
ly
 d
ru
g 
re
si
st
an
t
n:
 N
um
be
r o
f i
so
la
te
s s
eq
ue
nc
ed
#:
 N
um
be
r o
f m
ut
an
ts
N
S:
 N
on
-s
yn
on
ym
ou
s
S:
 S
yn
on
ym
ou
s
J Infect Dis. Author manuscript; available in PMC 2011 March 15.
